Liver International最新文献

{"title":"Correction to 'The First MASH Drug Therapy on the Horizon: Current Perspectives of Resmetirom'.","authors":"","doi":"10.1111/liv.70789","DOIUrl":"10.1111/liv.70789","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"46 8","pages":"e70789"},"PeriodicalIF":6.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13371144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148447772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Season-Aware Interpretation of Aminotransferases Should Not Become Season-Based Reassurance.","authors":"Mengzhu Dai, Qun Wang","doi":"10.1111/liv.70807","DOIUrl":"10.1111/liv.70807","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"46 8","pages":"e70807"},"PeriodicalIF":6.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13379794/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148471326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Rates of Advanced Chronic Liver Disease in Patients With Chronic Hepatitis D Virus Infection in Uzbekistan.","authors":"Malika E Khodjaeva, Aziza S Khikmatullaeva, Nargiz S Ibadullaeva, Gulnara K Khudaykulova, Munisa M Ilyasova, Kamila U Eshbayeva, Dildorakhon N Abdurakhmanova, Helenie Kefalakes, Petra Huber, Michael J Gebel, Erkin I Musabaev, Heiner Wedemeyer, Lisa Sandmann","doi":"10.1111/liv.70799","DOIUrl":"10.1111/liv.70799","url":null,"abstract":"<p><strong>Background and aims: </strong>Chronic hepatitis B virus (HBV) infection is endemic in Uzbekistan. Previous data showed a high prevalence of anti-hepatitis D virus (HDV) antibodies in HBsAg-positive individuals. Limited data are available on disease severity, treatment availability and hepatocellular carcinoma (HCC) prevalence in patients with chronic HDV infection in Uzbekistan.</p><p><strong>Methods: </strong>The Scientific Research Institute of Virology (SRIoV) is the leading medical and scientific reference centre for viral hepatitis in Uzbekistan. In this retrospective study, epidemiological, clinical and laboratory data were collected and analysed from all HBsAg-positive patients presenting to the SRIoV between June 2023 and May 2024. Data from HDV-coinfected and HBV-monoinfected patients were compared.</p><p><strong>Results: </strong>Data of 1393 individual patients were included. HDV coinfection was more prevalent than HBV-monoinfection (73.9% [n = 1030/1393]) vs. 26.1% [n = 363/1393]. HDV-infected patients were significantly younger (41.9 vs. 45.4, p < 0.001) and showed higher rates of cirrhosis (78.4% vs. 43.9%, p < 0.001) with the majority of patients being classified as Child-Pugh score B (57.8%). Only a minority of HDV-coinfected patients has ever received anti-HDV-directed treatment (0.4%, n = 4/1030). Consecutively, HDV RNA was detectable in 78.9% (812/1023) of patients. Quantitative HDV RNA was independently associated with ALT elevation > upper limit of normal. The HCC detection rate was low in both patient groups due to insufficient screening measures (HDV: n = 7/1030, HBV: n = 11/363).</p><p><strong>Conclusions: </strong>In this retrospective cohort of 1393 individual patients, HDV coinfection exceeds HBV monoinfection in prevalence and disease severity. Most HDV-infected patients present with advanced liver disease and currently lack access to HDV-directed therapy.</p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"46 8","pages":"e70799"},"PeriodicalIF":6.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148471258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to 'Fifteen Years of PNPLA3: Transforming Hepatology through Human Genetics'.","authors":"","doi":"10.1111/liv.70786","DOIUrl":"10.1111/liv.70786","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"46 8","pages":"e70786"},"PeriodicalIF":6.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13371134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148447780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laparoscopic or Open Liver Resection Versus Multibipolar Radiofrequency Ablation of HCC Within Milan Criteria on Cirrhosis.","authors":"Christian Hobeika, François Cauchy, Agnès Rode, Ephrem Salamé, Olivier Scatton, Lilian Schwarz, Panteleimon Papadopoulos, Arnaud Hocquelet, Anne-Frédérique Manichon, Christophe Aubé, Frederic Oberti, Angelo Della Corte, Alain Luciani, Suzanne Gay, Mickaël Lesurtel, Chetana Lim, Pierre Nahon, Nathalie Ganne-Carrié, Lorraine Blaise, Olivier Soubrane, Olivier Sutter, Raffaele Brustia, Louise Barbier, Alexis Laurent, Olivier Seror, Jean-Charles Nault","doi":"10.1111/liv.70802","DOIUrl":"10.1111/liv.70802","url":null,"abstract":"<p><strong>Background & aims: </strong>We compared multibipolar radiofrequency ablation (mbpRFA) with open liver resection (OLR) or laparoscopic liver resection (LLR) in patients with HCCs within Milan.</p><p><strong>Methods: </strong>This multicenter cohort study included patients treated by mbpRFA, OLR or LLR for HCC within the Milan Criteria, developed on advanced fibrosis in nine French centres between 2008 and 2018. Adjustments on HCC size/number, gender, age, ASA, HCV, HBV, metabolic syndrome, chronic alcohol intake, MELD score, serum AFP level, APRI score, cirrhosis, significant portal hypertension and HCC localization were performed using multivariable regressions with centre-robust variance and propensity score-based matching (3:1 nearest-neighbour with calliper < 0.1; effective ratios 2.18:1 and 2.43:1).</p><p><strong>Results: </strong>1040 patients were included (median age: 64 years; male 82.9%), with 606, 266 and 168 treated by mbpRFA, LLR and OLR. Most HCCs were solitary (84.8%) and on cirrhosis (89.2%). In months, the follow-up was 50.2 (95% CI: 45.3, 54.3), 43.3 (95% CI: 40.0, 48.6) and 47.4 (95% CI: 40.8, 58.7) for mbpRFA, LLR and OLR patients. After matching, OLR patients had similar overall survival (OS) (HR = 1.05 [CI 95% = 0.65, 1.69], p = 0.853), transplant-free survival (TFS) (HR = 0.91 [CI 95% = 0.56, 1.47]; p = 0.690) or recurrence-free survival (RFS) (HR = 0.99 [CI 95% = 0.69, 1.43]; p = 0.968) compared to mbpRFA patients but with more severe adverse events (RR = 2.58 [CI 95% = 1.16, 5.71]; p = 0.02) and mortality (RR = 4.51 [CI 95% = 1.16, 17.59]; p = 0.03). After matching, LLR patients had better OS (HR = 0.57 [CI 95% = 0.38, 0.88], p = 0.01) but similar TFS (HR = 0.77 [CI 95% = 0.55, 1.1]; p = 0.152) and more severe adverse events (RR = 2.61 [CI 95% = 1.15, 5.96]; p = 0.022) compared to mbpRFA patients. LLR patients had a better RFS (HR = 0.7 [CI 95% = 0.53, 0.91]; p = 0.009) than mbpRFA patients. When distant-only recurrences were considered in the mbpRFA patients, there was no significant difference in RFS (p = 0.087). The LLR survival benefit was consistent across pre-specified subgroups, with no interaction surviving correction for multiple testing.</p><p><strong>Conclusions: </strong>Minimally invasive modalities (LLR or mbpRFA) should be prioritized when treating early HCC. LLR maximizes oncological outcomes, but mbpRFA maintains optimal TFS with less morbidity.</p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"46 8","pages":"e70802"},"PeriodicalIF":6.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13386131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148536245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative MRI Intratumoral Heterogeneity Radiomics for Microvascular Invasion and Recurrence-Free Survival in HCC.","authors":"Ruishan Liu, Yangyang Xie, Lv Yue, Jing Jia, Lu Wang, Juan Liao, Hong-Wei Li, Hongchao Yao, Jie Zhang, Yanju Wang, Xingxiong Zhou, Wei Shi, Jiangqin Ma, Qian Chen, Xueqin Ma, Wei Zhou, Lian Yang, Gang Ning, Yong Zhou, Peixi Hu, Fan Li, Lihua Zhuo","doi":"10.1111/liv.70818","DOIUrl":"10.1111/liv.70818","url":null,"abstract":"<p><strong>Background and aims: </strong>Microvascular invasion (MVI) is a major determinant of postoperative recurrence and poor prognosis in hepatocellular carcinoma (HCC), yet MVI cannot be reliably identified before surgery: pathologic evaluation is invasive, prone to sampling bias, and available only after resection. We aimed to develop and evaluate a preoperative radiomics biomarker for noninvasive MVI prediction and postoperative risk stratification of recurrence-free survival.</p><p><strong>Methods: </strong>In this retrospective multicenter study, 567 patients with HCC from four centers were included. Based on pretreatment MRI and clinical variables available before surgery, radiomics models characterising the global tumour region (GTR) and intratumoral heterogeneity (ITH) were developed and integrated into a Fusion model for preoperative prediction of MVI. Discrimination, calibration, and clinical utility were assessed using AUC, calibration curves, and decision-curve analysis (DCA). Prognostic stratification was evaluated using C-index, time-dependent ROC analysis, and Kaplan-Meier analysis of recurrence-free survival, and benchmarked against the Barcelona Clinic Liver Cancer (BCLC), China Liver Cancer (CNLC), and American Joint Committee on Cancer (AJCC) staging systems.</p><p><strong>Results: </strong>The Fusion model showed higher discrimination than comparators in the validation and external test sets, achieving AUCs of 0.924 and 0.895, respectively. Ablation analyses showed incremental gains with the sequential addition of GTR features, ITH features, and clinical covariates. Fusion score-based stratification identified high- and low-risk groups with markedly divergent recurrence-free survival. In the external test set, the prognostic model achieved a C-index of 0.766 and time-dependent AUCs of 0.825 at 2 years and 0.878 at 5 years, showing higher discrimination than BCLC, CNLC, and AJCC staging (all p < 0.001). Performance remained robust across HBV status, histologic differentiation, and BCLC stage.</p><p><strong>Conclusions: </strong>A radiomics biomarker integrating global tumour phenotype, intratumoral heterogeneity, and preoperative clinical variables enables noninvasive preoperative MVI assessment and may complement morphology-based staging for recurrence risk stratification in HCC.</p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"46 8","pages":"e70818"},"PeriodicalIF":6.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13401225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148584266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Hepatic Venous Pressure Gradient Underestimate Direct Portal Pressure Gradient? A Focused Meta-Analysis.","authors":"Yu Zeng, Yi Shen, Xiaoli Fan, Xiaoze Wang","doi":"10.1111/liv.70800","DOIUrl":"10.1111/liv.70800","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"46 8","pages":"e70800"},"PeriodicalIF":6.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13366437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148437207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MASLD In PBC: A Shift From Liver-Centred to Cardiometabolic Risk Assessment?","authors":"Francesca Colapietro, Mauro Viganò","doi":"10.1111/liv.70817","DOIUrl":"10.1111/liv.70817","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"46 8","pages":"e70817"},"PeriodicalIF":6.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13396214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148579296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced Liver Fibrosis (ELF): From Prediction to Precision in MASLD.","authors":"Yasser Fouad, Mohamed AbdAllah","doi":"10.1111/liv.70810","DOIUrl":"10.1111/liv.70810","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"46 8","pages":"e70810"},"PeriodicalIF":6.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13379804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148471260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to 'Biopsy Before Autoimmune Hepatitis Withdrawal: The Estimand Matters'.","authors":"Yongqi Dong, Dan Zhou, LeYu Zhou, Li Yang, Yi Shen","doi":"10.1111/liv.70796","DOIUrl":"10.1111/liv.70796","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"46 8","pages":"e70796"},"PeriodicalIF":6.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13365632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148437270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}